Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,308 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
Calvo E, Moreno V, Flynn M, Holgado E, Olmedo ME, Lopez Criado MP, Kahatt C, Lopez-Vilariño JA, Siguero M, Fernandez-Teruel C, Cullell-Young M, Soto Matos-Pita A, Forster M. Calvo E, et al. Among authors: flynn m. Ann Oncol. 2017 Oct 1;28(10):2559-2566. doi: 10.1093/annonc/mdx357. Ann Oncol. 2017. PMID: 28961837 Free PMC article. Clinical Trial.
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).
Forster M, Hackshaw A, De Pas T, Cobo M, Garrido P, Summers Y, Dingemans AC, Flynn M, Schnell D, von Wangenheim U, Loembé AB, Kaiser R, Lee SM. Forster M, et al. Among authors: flynn m. Lung Cancer. 2018 Jun;120:27-33. doi: 10.1016/j.lungcan.2018.03.007. Epub 2018 Mar 9. Lung Cancer. 2018. PMID: 29748012 Free article. Clinical Trial.
An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours.
Arkenau HT, Italiano A, Mak G, Toulmonde M, Baird RD, Garcia-Corbacho J, Plummer R, Flynn M, Forster M, Wilson RH, Tosi D, Adenis A, Donaldson K, Posner J, Kawabata I, Arimura A, Deva S, Spicer J. Arkenau HT, et al. Among authors: flynn m. Eur J Cancer. 2018 Nov;103:17-23. doi: 10.1016/j.ejca.2018.07.134. Epub 2018 Sep 6. Eur J Cancer. 2018. PMID: 30196106 Free article. Clinical Trial.
Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
Olmedo ME, Forster M, Moreno V, López-Criado MP, Braña I, Flynn M, Doger B, de Miguel M, López-Vilariño JA, Núñez R, Kahatt C, Cullell-Young M, Zeaiter A, Calvo E. Olmedo ME, et al. Among authors: flynn m. Invest New Drugs. 2021 Oct;39(5):1275-1283. doi: 10.1007/s10637-020-01025-x. Epub 2021 Mar 11. Invest New Drugs. 2021. PMID: 33704620 Free PMC article. Clinical Trial.
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.
Milojkovic Kerklaan B, Slater S, Flynn M, Greystoke A, Witteveen PO, Megui-Roelvink M, de Vos F, Dean E, Reyderman L, Ottesen L, Ranson M, Lolkema MP, Plummer R, Kristeleit R, Evans TR, Schellens JH. Milojkovic Kerklaan B, et al. Among authors: flynn m. Invest New Drugs. 2016 Jun;34(3):329-37. doi: 10.1007/s10637-016-0344-9. Epub 2016 Apr 2. Invest New Drugs. 2016. PMID: 27039386 Clinical Trial.
A Multicentre Retrospective Study of Fulvestrant Use and Efficacy in Advanced/Metastatic Breast Cancer.
Lerner A, Keshwani K, Okines A, Sanderson B, Board RE, Flynn M, Sharkey E, Konstantis A, Roylance R, Hanna D, King J, Murphy R, Rehman F, Guppy AE, Westbury C, Takeuchi E, Spurrell E, Jayaweera HK, Raja F. Lerner A, et al. Among authors: flynn m. Clin Oncol (R Coll Radiol). 2022 Apr;34(4):261-266. doi: 10.1016/j.clon.2021.12.012. Epub 2022 Jan 10. Clin Oncol (R Coll Radiol). 2022. PMID: 35027287
1,308 results